

**Data for DCR: delivery of clinical (commercial) research: Q 2 2015-16**

REC No	Name of trial	Target recruitment	Date for recruitment to be complete	Trial status	If trial complete, was target hit?
12/SC/0687	A PHASE II, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF RO4602522 ADDED TO THE BACKGROUND THERAPY OF THE ACETYLCHOLINESTERASE INHIBITORS DONEPEZIL OR RIVASTIGMINE IN PATIENTS WITH MODERATE SEVERITY ALZHEIMER'S DISEASE	6	20/02/2014	Closed - in follow-up	Yes
10/H1102/85	Protocol H8AMCLZAO Continued Efficacy and Safety Monitoring of Solanezumab, an AntiAmyloid $\beta$ Antibody in Patients with Alzheimer's Disease	11	30/06/2015	Closed - in follow-up	Yes
13/NW/0560	Effect of Passive Immunization on the Progression of Mild Alzheimer's Disease: Solanezumab (LY2062430) Versus Placebo	12	28/02/2015	Closed - in follow-up	No
14/SC/0037	A PHASE III, RANDOMIZED, DOUBLEBLIND, PLACEBOCONTROLLED, PARALLELGROUP, MULTICENTER, EFFICIACY AND SAFETY STUDY OF GANTENERUMAB IN SUBJECTS WITH MILD ALZHEIMER'S DISEASE	4	31/01/2016	Open	
14/SC/0038	PET IMAGING SUBSTUDY ASSOCIATED WITH: A PHASE III, RANDOMIZED, DOUBLEBLIND, PLACEBOCONTROLLED, PARALLELGROUP, MULTICENTER, EFFICIACY, AND SAFETY STUDY OF GANTENERUMAB IN PATIENTS WITH MILD ALZHEIMER'S DISEASE	4	31/01/2016	Open	
14/EM/1082	Pfizer B2081011 - Phase 2a PF-05212377 safety& efficacy in Alzheimer's	5	31/10/2015	Suspended	
14/LO/1994	The AMARANTH Study	8	31/10/2016	Open	